Our data identifies the concomitant ablation of HRAS and NRAS as a new molecular alteration capable of triggering the development of RASopathy phenotypes in mice through a mechanism involving the hyperactivation of KRAS-dependent signaling. The gene discussed is HRAS; the disease is RASopathy.